
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure is a promising gene therapy company with a strong focus on developing treatments for various genetic and other diseases. The collaboration with Bristol Myers Squibb for cardiovascular diseases, as well as their pipeline programs for Huntington's Disease, Temporal Lobe Epilepsy, Fabry Disease, ALS, and Hemophilia B, show a diverse and promising portfolio. With the anticipated BLA filing for AMT-130 in the third quarter of 2026 and the expected commercial launch in the third quarter of 2027, followed by a potential ex-U.S. launch in 2027, we have increased our confidence in the commercial potential of their lead program and have raised our AMT-130 probability of success to 85%. However, risks to achieving our $80 price target include clinical development, commercialization, reimbursement, capital markets and dilution, pricing, and clinical trial risks.
Bears say
uniQure is facing potential delays in their product launch due to the FDA's stricter regulatory standards, indicated by the recent departure of key FDA personnel. Additionally, their financials are uncertain due to unpredictable future revenues and stock price volatility. Furthermore, their UK commercial planning may not be as advanced as previously thought, posing potential challenges for bringing their gene therapy to market.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares